KR20150036767A - A2a 효능제로서의 n-알킬 2-(이치환된)알키닐아데노신-5-유론아미드 - Google Patents

A2a 효능제로서의 n-알킬 2-(이치환된)알키닐아데노신-5-유론아미드 Download PDF

Info

Publication number
KR20150036767A
KR20150036767A KR20157004901A KR20157004901A KR20150036767A KR 20150036767 A KR20150036767 A KR 20150036767A KR 20157004901 A KR20157004901 A KR 20157004901A KR 20157004901 A KR20157004901 A KR 20157004901A KR 20150036767 A KR20150036767 A KR 20150036767A
Authority
KR
South Korea
Prior art keywords
alkyl
cyclopropyl
independently selected
alkylene
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR20157004901A
Other languages
English (en)
Korean (ko)
Inventor
로버트 톰슨
앤서니 뷰글홀
구오추안 왕
Original Assignee
루이스 앤드 클라크 파마슈티컬스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 루이스 앤드 클라크 파마슈티컬스, 인코포레이티드 filed Critical 루이스 앤드 클라크 파마슈티컬스, 인코포레이티드
Publication of KR20150036767A publication Critical patent/KR20150036767A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Nutrition Science (AREA)
KR20157004901A 2012-08-01 2013-07-31 A2a 효능제로서의 n-알킬 2-(이치환된)알키닐아데노신-5-유론아미드 Ceased KR20150036767A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261678605P 2012-08-01 2012-08-01
US61/678,605 2012-08-01
US201361787188P 2013-03-15 2013-03-15
US61/787,188 2013-03-15
PCT/US2013/053053 WO2014022577A1 (en) 2012-08-01 2013-07-31 N-alkyl 2-(disubstituted)alkynyladenosine-5-uronamides as a2a agonists

Publications (1)

Publication Number Publication Date
KR20150036767A true KR20150036767A (ko) 2015-04-07

Family

ID=50025663

Family Applications (1)

Application Number Title Priority Date Filing Date
KR20157004901A Ceased KR20150036767A (ko) 2012-08-01 2013-07-31 A2a 효능제로서의 n-알킬 2-(이치환된)알키닐아데노신-5-유론아미드

Country Status (15)

Country Link
US (1) US9067963B2 (enExample)
EP (1) EP2879683B1 (enExample)
JP (1) JP6545618B2 (enExample)
KR (1) KR20150036767A (enExample)
CN (1) CN104582709A (enExample)
AU (1) AU2013296420B2 (enExample)
BR (1) BR112015002249A2 (enExample)
CA (1) CA2880040A1 (enExample)
EA (1) EA027174B1 (enExample)
IL (1) IL236986A (enExample)
IN (1) IN2015DN00538A (enExample)
MX (1) MX367879B (enExample)
NZ (1) NZ703992A (enExample)
WO (1) WO2014022577A1 (enExample)
ZA (1) ZA201501350B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0610308A8 (pt) 2005-05-26 2017-04-25 Neuron Systems Inc Composições e métodos para o tratamento de doença retinal
US9814701B2 (en) 2009-12-11 2017-11-14 Aldeyra Therapeutics, Inc. Compositions and methods for the treatment of macular degeneration
US9822141B2 (en) * 2012-08-01 2017-11-21 Lewis And Clark Pharmaceuticals, Inc. N-alkyl 2-(disubstituted)alkynyladenosine-5-uronamides as A2A agonists
CN105120866B (zh) 2013-01-23 2020-02-14 奥尔德拉医疗公司 与毒性醛相关的疾病和治疗
WO2017035077A1 (en) 2015-08-21 2017-03-02 Aldeyra Therapeutics, Inc. Deuterated compounds and uses thereof
CA3022665A1 (en) 2016-05-09 2017-11-16 Aldeyra Therapeutics, Inc. Combination treatment of ocular inflammatory disorders and diseases
CN110431130A (zh) 2017-03-16 2019-11-08 奥尔德拉医疗公司 多晶型化合物和其用途
CN111356451A (zh) 2017-10-10 2020-06-30 奥尔德拉医疗公司 炎性病症的治疗
US12006298B2 (en) 2018-08-06 2024-06-11 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
CA3137301A1 (en) 2019-05-02 2020-11-05 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
US12098132B2 (en) 2019-05-02 2024-09-24 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
EP3988100A4 (en) * 2019-06-21 2023-07-26 Academy of Military Medical Sciences ADENOSINE COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT OR STEREOISOMERIDE THEREOF AND USE
EP4149470A4 (en) 2020-05-13 2024-04-24 Aldeyra Therapeutics, Inc. Pharmaceutical formulations and uses thereof
WO2024258897A1 (en) 2023-06-13 2024-12-19 Dem Biopharma, Inc. Alkoxypyridinyl and related compounds and their use in therapy
WO2025194015A1 (en) 2024-03-15 2025-09-18 Dem Biopharma, Inc. Heteroaryl modulators of gpr84 and uses thereof
WO2025194014A1 (en) 2024-03-15 2025-09-18 Dem Biopharma, Inc. Hetero aryl modulators of apmap and uses thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
JPS6299395A (ja) 1985-10-25 1987-05-08 Yamasa Shoyu Co Ltd ２−アルキニルアデノシンおよび抗高血圧剤
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
JPH02104783A (ja) * 1988-10-11 1990-04-17 Kanai Hiroyuki スチールコードおよびタイヤ
WO1990005526A1 (fr) 1988-11-15 1990-05-31 Yamasa Shoyu Kabushiki Kaisha Agent de traitement et de prophylaxie des troubles ischemiques du c×ur ou du cerveau
DE69022176T2 (de) 1989-06-20 1996-02-15 Toa Eiyo Ltd., Tokio/Tokyo Zwischenverbindung für 2-alkynyladenosinherstellung, herstellung dieser zwischenverbindung, herstellung von 2-alkynyladenosin aus diesem zwischenprodukt sowie stabiles 2-alkynyladenosinderivat.
US5189027A (en) 1990-11-30 1993-02-23 Yamasa Shoyu Kabushiki Kaisha 2-substituted adenosine derivatives and pharmaceutical compositions for circulatory diseases
JP3025557B2 (ja) * 1991-06-28 2000-03-27 ヤマサ醤油株式会社 ２‐アルキニルアデノシン誘導体
IT1254915B (it) 1992-04-24 1995-10-11 Gloria Cristalli Derivati di adenosina ad attivita' a2 agonista
JP2002173427A (ja) * 1998-09-01 2002-06-21 Yamasa Shoyu Co Ltd 眼疾患治療用医薬組成物
US6322771B1 (en) * 1999-06-18 2001-11-27 University Of Virginia Patent Foundation Induction of pharmacological stress with adenosine receptor agonists
ES2272449T3 (es) 2000-03-23 2007-05-01 Solvay Pharmaceuticals B.V. Derivados de 4,5-dihidro-1h-pirazol con actividad antagosnista de cb-1.
JP4514452B2 (ja) 2001-10-01 2010-07-28 ユニバーシティ オブ バージニア パテント ファウンデーション Ａ２ａアゴニスト活性を有する２−プロピルアデノシン・アナログおよびその組成物
WO2004022573A2 (en) 2002-09-09 2004-03-18 Cv Therapeutics, Inc. Adenosine a3 receptor agonists
CA2576826C (en) 2004-08-02 2014-09-30 University Of Virginia Patent Foundation 2-propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity
WO2006091896A2 (en) * 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Pyridyl substituted xanthines
WO2007120972A2 (en) * 2006-02-10 2007-10-25 University Of Virginia Patent Foundation Method to treat sickle cell disease
ES2361886T3 (es) * 2006-06-27 2011-06-24 Cbt Development Limited Profármacos adenosina acetil 2',3'-metilideno novedosos para uso como profármacos para agonistas del receptor adenosina.
WO2008124150A1 (en) * 2007-04-09 2008-10-16 University Of Virginia Patent Foundation Method of treating enteritis, intestinal damage, and diarrhea from c. difficile with an a2a adenosine receptor agonist
NZ580940A (en) 2007-05-17 2012-02-24 Gilead Palo Alto Inc Process for preparing an a2a-adenosine receptor agonist and its polymorphs
US8058259B2 (en) 2007-12-20 2011-11-15 University Of Virginia Patent Foundation Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
US8293720B2 (en) 2007-12-20 2012-10-23 Dogwood Pharmaceuticals, Inc. Substituted 4-{3-[6-amino-9-(3, 4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
AU2010266313A1 (en) * 2009-06-30 2012-01-19 Forest Laboratories Holdings Limited Alkoxy-carbonyl-amino-alkynyl-adenosine compounds and derivatives thereof as A2A R agonists

Also Published As

Publication number Publication date
EP2879683A4 (en) 2016-04-20
EA201590205A1 (ru) 2015-06-30
EP2879683A1 (en) 2015-06-10
ZA201501350B (en) 2016-12-21
AU2013296420A1 (en) 2015-02-12
EA027174B1 (ru) 2017-06-30
MX367879B (es) 2019-09-10
US20140037538A1 (en) 2014-02-06
WO2014022577A1 (en) 2014-02-06
BR112015002249A2 (pt) 2017-07-04
CA2880040A1 (en) 2014-02-06
IN2015DN00538A (enExample) 2015-06-26
IL236986A (en) 2017-06-29
EP2879683B1 (en) 2020-01-22
JP2015524440A (ja) 2015-08-24
JP6545618B2 (ja) 2019-07-17
MX2015001370A (es) 2016-04-26
AU2013296420B2 (en) 2017-12-07
US9067963B2 (en) 2015-06-30
NZ703992A (en) 2018-04-27
CN104582709A (zh) 2015-04-29

Similar Documents

Publication Publication Date Title
KR20150036767A (ko) A2a 효능제로서의 n-알킬 2-(이치환된)알키닐아데노신-5-유론아미드
US10710987B2 (en) Hydrochloride salt form for EZH2 inhibition
US20230118795A1 (en) Aryl or heteroaryl pyridone or pyrimidine derivative, preparation method and use thereof
HU227972B1 (en) Phthalazines with angiogenesis inhibiting activity and pharmaceutical compositions containing them
WO2021213317A1 (zh) Hpk1抑制剂及其制备方法和用途
CN117561244A (zh) 异吲哚啉酮类化合物及其用途
TW202302587A (zh) 異喹啉酮類化合物及其用途
WO2023088408A1 (zh) 选择性parp1抑制剂及其应用
TW202442231A (zh) Mta協同性prmt5抑制劑
US9822141B2 (en) N-alkyl 2-(disubstituted)alkynyladenosine-5-uronamides as A2A agonists
EP4393924A1 (en) Imidazo [1,2-a] pyrazine or pyrazolo [1,5-a] pyrimidine derivative and use thereof
US8263762B2 (en) Alkoxy-carbonyl-amino-alkynyl-adenosine compounds and derivatives thereof as A2AR agonists
CN108864114B (zh) 选择性a2a受体拮抗剂
WO2025176178A1 (zh) 一类并环结构取代的新型cdk12/13共价抑制剂或其药物组合物和应用
HK40109783A (en) Hydrochloride salt form for ezh2 inhibition
WO2019072130A1 (zh) 一种1,2,4-三氮唑类化合物
HK1227873B (en) Hydrochloride salt form for ezh2 inhibition
HK1227873A1 (en) Hydrochloride salt form for ezh2 inhibition

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20150225

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20180731

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20191223

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20200407

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20191223

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I